ReviewActa pharmaceutica Sinica. B2016
Influence of physical properties of carrier on the performance of dry powder inhalers.
Review in Acta pharmaceutica Sinica. B, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed.
- Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate?The AAPS journal · 2021Trial
- Artificial Intelligence-Based Optimization of Pulmonary Drug Delivery Performance in Smart Inhaler Drug-Device Combination Systems.Pharmaceutics · 2026Review
- Nanometer Layer Coating to Lactose Particles for Optimization of Dexamethasone Pulmonary Delivery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Continuous Electrospraying of Inhalable Biological Drug Products: Novel Formulation and Manufacturing Technology.Pharmaceutical research · 2026Article
- Development of Proniosomal Dry Powder for Dual Pulmonary Delivery of Salbutamol Sulfate and Carvacrol: A Design of Experiment Approach.Pharmaceutical research · 2026Article
- The Application of Machine Learning in the Development of Co-Amorphous Dry Powder Inhalation.AAPS PharmSciTech · 2026Article
- Inhalable Chitosan Microparticles: A Spray-Drying Approach for Enhanced Pulmonary Delivery of Rifampicin.ACS omega · 2026Article
- Applications of AI/ML in accelerating the development of pulmonary drug delivery system.Acta pharmaceutica Sinica. B · 2026Review
- Inhalable nanoparticle-based drug delivery system for non-small cell lung cancer therapy: promises and challenges.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2025Review
- Recent Developments in Pharmaceutical Spray Drying: Modeling, Process Optimization, and Emerging Trends with Machine Learning.Pharmaceutics · 2025Review
- Charged Particle Dynamics in Dry Powder Inhalers.Molecular pharmaceutics · 2025Article
- [Advances in inhalable nano-formulations].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2025Review
- Fabrication and evaluation of solidified nanoemulsion designs for systemic delivery of atorvastatin through the lung.Scientific reports · 2025Article
- Preparation and Study of Erythromycin Dry Powder Inhaler Based on Ternary Complex Structure.AAPS PharmSciTech · 2025Article
- Assessment of Innovative Dry Powders for Inhalation of a Synergistic Combination AgainstPharmaceutics · 2025Article
- Particle surface coating for dry powder inhaler formulations.Expert opinion on drug delivery · 2025Review
- Scale-Up and Postapproval Changes in Orally Inhaled Drug Products: Scientific and Regulatory Considerations.Journal of aerosol medicine and pulmonary drug delivery · 2025Review
- Polyelectrolyte Complex Dry Powder Formulations of Tobramycin with Hyaluronic Acid and Sodium Hyaluronate for Inhalation Therapy in Cystic Fibrosis-Associated Infections.Antibiotics (Basel, Switzerland) · 2025Article
- Evaporation Kinetics and Final Particle Morphology of Multicomponent Salt Solution Droplets.The journal of physical chemistry. A · 2025Article
- Different Carriers for Use in Dry Powder Inhalers: Characteristics of Their Particles.Journal of aerosol medicine and pulmonary drug delivery · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dry powder inhalers (DPIs) offer distinct advantages as a means of pulmonary drug delivery and have attracted much attention in the field of pharmaceutical science. DPIs commonly contain micronized drug particles which, because of their cohesiveness and strong propensity to aggregate, have poor aerosolization performance. Thus carriers with a larger particle size are added to address this problem. However, the performance of DPIs is profoundly influenced by the physical properties of the carrier, particularly their particle size, morphology/shape and surface roughness. Because these factors are interdependent, it is difficult to completely understand how they individually influence DPI performance. The purpose of this review is to summarize and illuminate how these factors affect drug-carrier interaction and influence the performance of DPIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.